Aquestive reports positive human factors, PK results for Anaphylm epinephrine sublingual film in healthy volunteers

• Aquestive Therapeutics reported positive topline results from a human factors validation study and a pharmacokinetic study for Anaphylm sublingual film.
• Results were presented as topline findings now, supporting a planned NDA resubmission in Q3 2026.
• Revised packaging and instructions improved usability in simulated emergency use, addressing issues cited in an FDA complete response letter.
• Self-administration performed comparably to clinician administration in healthy volunteers, supporting real-world use without injection.
• Incorrect placement still produced a clinically meaningful response broadly consistent with injectable epinephrine, strengthening the risk-mitigation case.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.